Dollar and Senses: Pharmaceutical Product Design is Becoming Vivid by Schreiber, Stacey L.
 




(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Dollar and Senses: Pharmaceutical Product Design is Becoming
Vivid (2003 Third Year Paper)
Accessed February 19, 2015 9:38:02 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846778
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAADollars and Senses:




This paper is submitted in satisfaction of both the Food and Drug Law course requirement and the Third
Year Paper requirement
1Abstract: Prilosec purple, Viagra blue, and Prozac green and cream: pharmaceutical
product design is on the rise, and the future is even brighter. As design features come
into view, protection against copying is critical to maintaining the eﬀectiveness of these
source-identifying marks. The current state of trademark law allows drug manufacturers
to prevent competitors from producing similar medications with the same appearance or
identifying design feature. However, while most courts have been increasingly sympathetic
to product design protection, these tools are not yet being fully utilized by the pharma-
ceutical industry. This paper describes the current state of trademark and trade dress
protection of pharmaceutical product design, such as color, shape, and ﬂavor and provides
insight into why pharmaceutical companies have yet to take full advantage of available
trademark and trade dress protection.
2I. Introduction
Prilosec purple, Viagra blue, and Prozac green and cream: pharmaceutical product design is on the rise,
and the future is even brighter. As design features come into view, protection against copying is critical
to maintaining the eﬀectiveness of these source-identifying marks. Trademark law increasingly permits
drug manufacturers to prevent competitors from producing similar medications with the same appearance
or identifying design feature. However, while most courts have been increasingly sympathetic to product
design protection, these tools are not yet being fully utilized by the pharmaceutical industry.
When a drug is introduced, the manufacturer’s monopoly is assured through patent protection, but once
the patent expires, the market is often ﬂooded with lower-priced versions of the same drug1produced by
competitors.2In 1984, Congress introduced the Drug Price Competition and Patent Term Restoration Act,
also known as the Hatch-Waxman Act, facilitating the process for generic entrance into the market.3The act
also served to legitimate generic pharmaceuticals; the acknowledgement that generics are considered safe and
1Whether or not generic versions of the name brand pharmaceuticals are actually the “same” can often be a matter of dispute.
The FDA requires that generic drugs be “identical, or bioequivalent to a brand name drug in dosage form, safety, strength,
route of administration, quality, performance characteristics and intended use.” http://www.fda.gov/cder/ogd/index.htm
(last visited Mar. 3, 2003). The U.S. Supreme Court deﬁned drugs as bioequivalent “if, when administered in equal amounts
to the same individual, they reach general circulation at the same relative rate and to the same relative extent.” Inwood Labs.,
Inc. v. Ives Labs., Inc., 456 U.S. 844, 848 n.5 (1982) (citing Remington’s Pharmaceutical Sciences 1368 (15th ed. 1975).
However, name brand pharmaceutical companies may claim that their products remain superior due to an even higher quality
standard than required by the government regulator. See American Home Products Corp. v. Chelsea Labs., Inc., 572 F. Supp.
278, 280 (D.N.J. 1982) aﬀ’d mem 722 F.2d 730 (3rd Cir. 1983) (accepting the plaintiﬀ-brand manufacturer’s assertion that
its preparation of “conjugated estrogen” is of a higher quality and held to more stringent standards than those required for a
U.S.P. label).
2Generic drug companies can capture 50% of a brand manufacturer’s unit sales within a year of patent expiration. Shawn
Tully, Why Drug Prices Will Go Lower, Fortune, May 3, 1993, at 56.
3Along with oﬀering brand name companies a patent extension to compensate for FDA regulatory delays, the Hatch-Waxman
Act expedited the FDA approval process for generic equivalents by creating an abbreviated new drug application, ANDA, and
allowing the generic manufacturer to use data from the original, brand drug’s application. This enables generics to enter the
market as soon as the brand drug’s patent expires. See Gregory J. Glover, Impact of Hatch-Waxman Goes Beyond Generics,
National Law Journal, June 6, 1997, at C7.
3equivalent to brand name drugs, increased public acceptance, awareness, and thus, consumption of generics.
A 1998 Congressional Budget Oﬃce Study found that since the enactment of Hatch-Waxman, the generic
market share rose from 18.6% to 42.6%.4Consequently, brand name pharmaceuticals rapidly lose market
shares as cheaper generics are introduced. From 1991 to 1993, within one year of patent expiration, brand
name drugs lost 44% of their market share on average.5More recently, Prozac sales decreased by 85% in the
three months after generic competition began.6Moreover, whereas prior to Hatch-Waxman, only 35% of top
selling pharmaceuticals had generic equivalents, almost all successful sellers now compete with generics.7This
increase in generic competition underscores the need for brand name manufacturers to distinguish their
products.
As a patent term nears expiration, manufacturers can turn their attention to a unique design to maintain
sales; although generic manufacturers may reproduce drugs, they are not necessarily entitled to mimic the
appearances of prescription drugs. Since 1997, the FDA has permitted manufacturers of prescription drugs
to use direct-to-consumer (DTC) advertising,8and this has increased public recognition of brand names and
product design. In the year 2000, pharmaceutical companies spent $2.5 billion on such marketing in the
United States,9and several promotional strategies aimed at the public have focused on appearance as well
4This study examined drugs that comprise approximately 70% of prescription drug sales through retail pharmacies and
considered drugs in the form of “easily countable units.” Melissa C. Popolillo, Government Study Reveals Generics’ Impact
on Industry, Drug Store News, Oct. 19, 1998, at CP20 (citing the CBO July 1998 Study, How Increased Competition from
Generic Drugs has Aﬀected Prices and Returns in the Pharmaceutical Industry).
5Id.
6Generics Threat to Drug Firms, Business, Apr. 21, 2002, at 12.
7Popolillo, supra note 4, at CP20.
8Previously, the FDA’s requirement that prescription drug ads list all of the possible side eﬀects prevented drug manufacturers
from being able to condense all of the information into a short television or radio spot. However, the changes relaxed the
disclosure requirements, allowing drug manufacturers to promote their products directly to the public. See David Stout, Drug
Makers Get Leeway on TV Ads, N.Y. Times, Aug. 9, 1997, at Sec. 1, p.35, column 5.
9Pharma Brands Capture Hearts and Minds, IMS HEALTH Global Services, at
http://www.ims-global.com/insight/news story/0109/news story 010925.htm (last visited Feb. 11, 2003).
4as function.
This paper describes the current state of trademark and trade dress protection of pharmaceutical product
design, such as color, shape, and ﬂavor and provides insight into why pharmaceutical companies have yet
to take full advantage of available trademark and trade dress protection. Part II discusses the growing
acceptance of trade dress protection for pharmaceuticals. Part III focuses on the seismic change in trademark
doctrine instituted by Qualitex v. Jacobson Products,10which permitted registration and protection of color
per se. Part IV discusses the subsequent interpretations of Qualitex and suggests that other single-feature
non-traditional marks may receive increased protection in light of this watershed opinion. Finally, with a
few exceptions, the pharmaceutical industry overall has been hesitant to take advantage of the increasingly
expansive bounds of trademark doctrine, and Part V oﬀers possible explanations for the industry’s inaction.
As the breadth of trademark and trade dress protection continues to expand, protection for aspects of
pharmaceutical design that identify its source should increase, as should pharmaceutical companies’ interest
in pursuing this protection.
II. Prior Case Law on Trade Dress Protection
Courts have generally been sympathetic to claims against manufacturers of generic “look alike” pharmaceu-
ticals. In fact, many courts aﬃrmed manufacturers’ rights to brand their products even after Congress and
the FDA proclaimed their support for generic drugs in the Hatch Waxman Act. When generic drugs are
produced and distributed in the same color, shape, and texture as the original, the name brand manufacturer
often brings suit claiming a violation of §43(a) of the Lanham Act and violations of the relevant state unfair
competition laws.11Federal unfair competition law set out in section 43(a) of the Lanham Act states:
10514 U.S. 159 (1995).
1115 USC § 1125(a) (2002); see, e.g., American Home Products v. Chelsea Labs., Inc., 572 F. Supp. at 279.
5Any person who, on or in connection with any goods or services, or any container for goods, uses
in commerce any word, term, name, symbol, or device, or any combination thereof, or any false
designation of origin, false or misleading description of fact, or false or misleading representation of
fact, which –
(A) is likely to cause confusion, or to cause mistake, or to deceive as to the aﬃliation, con-
nection, or association of such person with another person, or as to the origin, sponsorship,
or approval of his or her goods, services, or commercial activities by another person, or
(B) in commercial advertising or promotion, misrepresents the nature, characteristics, qual-
ities, or geographic origin of his or her or another person’s goods, services, or commercial
activities,
shall be liable in a civil action by any person who believes that he or she is or is likely to be damaged
by such act.12
Federal unfair competition encompasses the torts of “unprivileged imitation” and “passing oﬀ.” Unprivileged
imitation requires the trade dress in question to serve no function other than source identiﬁcation, to be
distinctive – either inherently or through the acquisition of secondary meaning; moreover, there must be a
likelihood of consumer confusion.13Unfair competition can also be proved independently from unprivileged
imitation through a showing of “passing oﬀ.”14As a result, a generic manufacturer can be held responsi-
ble for promoting illegal substitutions by pharmacists without evidence of a manufacturer’s direct involve-
ment.15Many plaintiﬀs have been successful in their claims of §43 violations, with some winning preliminary
injunctions prior to trial.16However, despite the growing sympathy of district and appellate courts for brand
name manufacturers, the Supreme Court has remained evasive. The highest court has heard only one case
on trade dress infringement of look-alike drugs in more than ﬁfty years, and its decision, which favored the
13See, e.g., American Home Products v. Barr Labs., 656 F. Supp. 1058, 1061 (D.N.J. 1987) (citing American Greetings
Corp. v. Dan-Dee Imports, Inc., 807 F.2d 1136, 1140 (3rd Cir. 1986) (requiring “that the feature or overall combination of
features imitated is non-functional, that it has acquired secondary meaning, and that members of the consuming public are
likely to confuse the source of the product bearing the imitating feature or combination with the source of the product bearing
the imitated feature or combination”).
14Marion Labs., Inc. v. Michigan Pharmacal Corp., 338 F. Supp. 762, 769 (E.D. Mich. 1972).
15See, e.g., Hoﬀman-La Roche, Inc. v. Premo Pharm. Labs., Inc., 1980 U.S. Dist. LEXIS 16851, at *41 (D.N.J. 1980).
16See id.; Ross-Whitney Corp. v. Smith Kline & French Labs., 207 F.2d 190 (9th Cir. 1953); McNeil-PPC, Inc. v. Granutec,
Inc., 919 F. Supp. 198 (E.D.N.C. 1995); Pennwalt Corp. v. Zenith Labs., Inc., 472 F. Supp. 413 (E.D. Mich. 1979).
6manufacturer of the look-alike, was ultimately decided on a mere technicality.17Overall, the precedent on
trade dress protection for pharmaceuticals sets a cautiously optimistic tone for brand name use of product
design as a source-identiﬁer.
A. Secondary Meaning
A name brand pharmaceutical company’s ﬁrst hurdle in achieving trade dress protection is establishing
secondary meaning for a drug’s appearance.18The United States Supreme Court has deﬁned secondary
meaning as a showing that “in the minds of the public, the primary signiﬁcance of a product feature or term
is to identify the source of the product rather than the product itself.”19However, the public need not be
able to identify this source by name; the court in CIBA-GEIGY v. Bolar Pharmaceuticals noted that “‘to
establish secondary meaning it is not necessary for the public to be aware of the name of the manufacturer
which produces a product; rather, it is suﬃcient if the public assumes that the product comes from a single
though anonymous, source.”’20 Secondary meaning can be established using a variety of evidence. Courts
17Inwood Labs., 456 U.S. at 856.
18It is theoretically plausible that courts could view a drug’s unique color, shape and texture as inherently distinctive, thus
deserving of protection without a showing of secondary meaning. However, this possibility has rarely been mentioned, and was
rejected in Florida Breckenridge, Inc. v. Solvay Pharmaceuticals, Inc.. 1997 U.S. Dist. LEXIS 17574, at *11-15 (S.D. Fla.
1997) (ﬁnding that while the overall appearance is distinctive and arbitrary, third party use of similar combinations weighs
against a ﬁnding of inherently distinctive trade dress).
19Inwood Labs., 456 U.S. at 851 n.11 (citing Kellogg Co. v. National Biscuit Co., 305 U.S. 111, 122 (1938)).
20CIBA-GEIGY v. Bolar Pharm., 547 F. Supp. 1095, 1113 (D.N.J. 1982), aﬀ’d,747 F.2d 844 (3rd Cir. 1984), cert denied, 105
S.Ct. 2678 (1985) (citing Processed Plastic Co. v. Warner Communications, Inc., 675 F.2d 852, 856 (7th Cir. 1982) (emphasis
added)) (ﬁnding that the blue and white opaque capsules and pink and white opaque capsules were suﬃciently recognizable
and had attained secondary meaning).
7generally consider factors such as extensive sales of a product sold with a particular trade dress,21extensive
marketing,22widespread distribution of starter kits,23and consumer surveys,24to assess whether a drug’s
unique appearance has achieved secondary meaning.
The ability of such factors to link a drug’s trade dress with a single source has been questioned, but the
Third Circuit precedent for accepting these factors remains. While the majority in the CIBA-GEIGY appeal
agreed with the district court that the association of the drug’s trade dress with the drug’s brand name and
manufacturer met the requirement for showing secondary meaning, the dissent dismissed these factors as
“merely indicia of secondary meaning” and argued that the association “probably” served to identify only the
function of the medication “(e.g., ‘my blood pressure medicine’). ” 25InapreviousThirdCircuitdecision, SK&F
v. Premo Pharmaceutical Laboratories, the court found that a name brand drug’s appearance served to
identify the drug as a particular diuretic, thus having acquired secondary meaning.26The dissent in CIBA-
GEIGY attempts to establish that in this case, unlike in SK&F, an unrelated name brand drug looked
similar to the name brand drug in question, thus preventing the trade dress from being identiﬁed with a
21See id.; American Home Products v. Chelsea, 572 F. Supp. at 281 (ﬁnding that unique trade dress plus long usage, alone,
can establish secondary meaning).
22See Par Pharm., Inc., v. Searle Pharm., Inc., 1985 U.S. Dist. LEXIS 16648, at *7-8 (N.D. Ill. 1985) (holding that evidence
of a $2,000,000 spent on marketing of a particular blue-colored tablet was one of several factors which made a claim of secondary
meaning likely to succeed at trial); Boehringer Ingelheim G.m.b.H v. Pharmadyne Labs., 532 F. Supp. 1040 (D.N.J. 1980)
(ruling that marketing expenses of over $15 million promoting both the drug’s trademark and orange-colored, smoothly rounded,
biconvex trade dress was “highly persuasive evidence” of secondary meaning).
23See id. at *8. (stating that the distribution of 1.1 million starter kits was a factor increasing the likelihood of ﬁnding of
secondary meaning); American Home Products v. Chelsea, 572 F. Supp. at 281, 285 (noting that secondary meaning will likely
be established at trial “especially” because of the distribution of millions of starter kits).
24See McNeil-PPC, 919 F. Supp. at 202.
25CIBA-GEIGY v. Bolar Pharm. Co., 747 F.2d 844, 856-857 (3rd Cir. 1984).
26SK&F, Co. v. Premo Pharm. Labs., Inc., 625 F.2d 1055, 1064 (3rd Cir. 1980).
8single source.27However, the majority-aﬃrmed district court decision found the existence of a similar-looking,
diﬀerent drug to be irrelevant because the two contained diﬀerent ingredients and each bore a name brand
– thus lessening the likelihood of illegal substitution by a pharmacist.28
The district court in CIBA-GEIGY also noted that a competitor’s copying of the original trade dress
suﬃced to demonstrate secondary meaning.29The district court reasoned that a product’s appearance would
not be copied if it had no value, and it is this value that translates into secondary meaning.30 However,
copying has not always been viewed as probative of secondary meaning. In Par Pharmaceutical v. Searle
Pharmaceuticals, the court stated that copying alone may be insuﬃcient to show secondary meaning, albeit
constituting strong evidence thereof.31Moreover, in Marion Laboratories v. Michigan Pharmacal Corp., the
court rejected the claim that secondary meaning of the plaintiﬀ’s trade dress had been achieved despite the
court’s acknowledgement that several companies – including the defendant company – copied the plaintiﬀ’s
capsule’s brown and clear appearance as well as other aspects of the drug itself.32The court deemed the
secondary meaning survey insuﬃcient because the survey was taken after the defendant’s competing brown
and white capsule had entered the market.33Evidence of promotional strategies and expenses were similarly
dismissed due to a lack of “direct evidence” showing that this marketing took place prior to the defendant’s
27CIBA-GEIGY, 747 F.2d at 858 n.3.
28Id. at 851-852, 858 n.3.
29CIBA-GEIGY, 547 F.Supp. at 1113.
30Id.
31Par Pharm., 1985 U.S. Dist. LEXIS 1664, at *9-10 (N.D. Ill. 1985); see also McNeil-PPC, 919 F. Supp. at 202 (holding
that copying alone leads only to a presumption of secondary meaning, but evidence of copying plus a survey of secondary
meaning would likely succeed to show secondary meaning in a trial on the merits).
32Marion Labs., Inc. v. Michigan Pharmacal Corp., 338 F. Supp. 762, 769 (E.D. Mich. 1972) (granting defendant-look-alike





Even if a product’s distinctive appearance has acquired secondary meaning, an item will not enjoy trade
dress protection if the item’s distinguishing features serve a functional purpose. The standard for function-
ality entails being “essential to the use or purpose of the article” or “aﬀect[ing] the cost or quality of the
article.”35Generally, courts have accepted the notion that a drug’s distinctive trade dress is arbitrary and
non-functional. However, the Supreme Court has never actually adopted this rationale. Overall, despite
the Supreme Court’s lack of clear guidance on the issue, branded pharmaceuticals are likely to prevail over
assertions of therapeutic functionality.
Certain trade dress attributes have nevertheless been denied protection because of their functionality. In
SK&F Laboratories v. Clark &Clark, the Third Circuit held that each aspect of the tablet in question’s
trade dress served a function other than source identiﬁcation: the beveled edges prevented crumbling, the
concave bottom facilitated breaking the tablet into smaller doses, the scoring also facilitated breaking the
tablet, the round shape was less costly to manufacture and the whiteness was the tablet’s natural color –
thus functional.36 The therapeutic functions of a drug’s appearance have historically gained court accep-
tance. In 1924, the US Supreme Court deemed the combination of liquid quinine and chocolate functional
because the ﬂavoring “supplies the mixture with a quality of palatability for which there is no equally sat-
34Id.
35Inwood Labs., 456 U.S. at 850 n.10.
36Smith Kline & French Labs. v. Clarke & Clarke, 157 F.2d. 725, 730 (3rd Cir. 1946).
10isfactory substitute.”37Moreover, in 1959, the Second Circuit found the pink color of Pepto-Bismol to be
functional.38The court focused on the fact that that the pink color was intended to “‘present a pleasing
appearance,”’ reaching the odd conclusion that “a ﬁnding of functional value might well be made because
a rejected stomach medicine scarcely has a fair opportunity to fulﬁll its function.”39A district court also
ruled, without explanation, that the amber color of mouthwash was functional.40 However, not every court
has accepted the argument that pharmaceutical trade dress serves a therapeutic or practical function. As
early as 1953, the Ninth Circuit decided not to consider whether the “valentine-like” shape of a tablet
served a function in preventing dropped pills from rolling away.41The court instead rejected a functionality
claim simply because the purpose of using this particular shape and color was to identify the brand name
product.42In Biocraft Laboratories v. Merck & Co., the generic manufacturer urged the court to accept the
therapeutic value of pharmaceutical trade dress in the context of psychotropic drugs.43The court rejected
this claim on several grounds.44As a general matter, the court deferred to the FDA in determining whether
certain drugs are most eﬀective in particular colors.45The court also noted that there is no support in current
law or custom for the notion that each medication should be distributed with only one type of trade dress
37William R. Warner & Co. v. Eli Lilly & Co., 265 U.S. 526, 529 (1924).
38Norwich Pharmacal Co. v. Sterling Drug, Inc., 271 F.2d 569, 572 (2nd Cir. 1959).
39Id.; It should be noted, however, that the driving force behind the Norwich decision was the belief that color alone should
not be protected – a decision which has since been overruled by the Supreme Court in Qualitex, 514 U.S. 159 (1995). See infra
Part III.
40Warner Lambert Co. v. McCrory’s Corp., 718 F. Supp. 389 (D.N.J. 1989). Note that the only discussion following the
ﬁnding of functionality focused on the fact that colors are not protectable.
41Ross-Whitney, 201 F.2d at 196.
42Id. at 197.
43Biocraft Labs., Inc., v. Merck & Co., Inc., 532 F. Supp. 1068, 1075-1076 (D.N.J. 1980).
44Id. at 1075-1077.
45Id. at 1076.
11(regardless of the manufacturer).46Focusing on the speciﬁc drugs and colors at issue, the court questioned
the validity and feasibility of the arguments presented: one of the studies relied on at trial, despite having
statistically insigniﬁcant results, showed that anxiety patients preferred green tablets, with yellow ranking
the least preferable, while those suﬀering from depression preferred yellow.47Since the medication in ques-
tion is indicated for depression accompanied by anxiety, this ﬁnding was deemed confusing and ultimately
disregarded.48 Courts have also rejected the claim that using diﬀerent colors for diﬀerent dosages renders
a drug’s trade dress functional. In Biocraft Laboratories, the manufacturer of a brand look-alike asserted
that the each color served to identify a particular dosage, and thus lacked protectable status.49However, the
court responded that:
while color code systems per se are doubtless in the public domain in the sense that a manufacturer
using a color code cannot prevent another manufacturer from using a diﬀerent color code, the
uniqueness of each color code for a given manufacturer and product reﬂects identity and source,
which may not be copied.50
As there is no set industry standard, the court ruled that the particular selection of colors was arbitrary and
non-functional.
Generic manufacturers have also unsuccessfully argued that pharmaceutical trade dress generally serves a
function identifying a type of medication – rather than a brand – and that standardization of such trade
dress is socially desirable. In CIBA-GEIGY, the district court’s rejection of the argument that doctors and
pharmacists would prescribe medication simply based on its appearance was upheld on appeal.51The notion
46Id. at 1076.
47Id. at 1076.
48The court further deﬂates the argument of colors’ therapeutic values by noting that one such spectrum is now on display
at the National Museum of Quackery maintained by the St. Louis (Missouri) Medical Society. Id. at 1076 (citing N.Y. Times,
Aug. 17, 1980, p. 36).
49Biocraft Labs., 532 F. Supp. at 1070.
51CIBA-GEIGY, 747 F.2d at 851.
12that patients would be unable to adjust to new colors for the same medication has also been rejected, with
the court ruling that, without evidence to the contrary, the court is “unwilling to believe it to be beyond
the ability of patients to stop associating orange with their heart medicine and start thinking of green as the
color of the pill taken for their heart condition.”52 The claim that generic look-alikes avoid patient anxiety
caused by switching from brand to generic medication has been similarly rejected. In SK&F v. Premo,
the Third Circuit refused to accept this argument, noting that most states require consumer notiﬁcation
of any substitution of generic for name brand medication.53If a patient is informed about a substitution,
the fact that the new, substituted medication looks diﬀerent is not expected to aﬀect the patient’s level of
anxiety.54Similar reasoning can be found in Boehringer Ingelheim v. Pharmadyne.55
Critics of pharmaceutical trade dress protection have also suggested that
standardization can facilitate emergency room identiﬁcation of drugs in the event of overdose, yet courts have
rejected this claim of functionality as well. In Boehringer Ingelheim, the court dismissed this contention both
because the medication at issue was unlikely to cause an emergency room overdose problem and because the
color was unlikely to aid in identifying the active ingredient even if overdose did occur.56In Hoﬀman-La Roche
v. Premo Pharmaceutical Laboratories, the court rejected the same argument of trade dress functionality
in emergency rooms, simply deeming it “unpersuasive.”57In SK&F v. Premo, this same contention was
52Boehringer Ingelheim, 532 F. Supp. at 1049.
53SK&F v. Premo, 625 F.2d at 1061; see also Hoﬀman-La Roche Inc. v. Premo Pharm. Labs., Inc., 1980 U.S. Dist. LEXIS
16851, at *39 (D.N.J. 1980).
54Id.
55Boehringer Ingelheim, 532 F. Supp. at 1047-1049.
56Id. at 1049.
57Hoﬀman-La Roche, 1980 U.S. Dist. LEXIS 16851, at *39.
13dismissed because the generic version in question was not bioequivalent.58As a result, if the medications
have the same appearance, an emergency room technician would have great diﬃculty ascertaining which
type of the drug has been ingested and would not at all be aided by color standardization.
Despite the plethora of cases rejecting the public policy arguments for ﬁnding functionality, the US Supreme
Court has not yet adopted the same reasoning. In Inwood v. Ives, the court appears sympathetic to the
district court’s view that the blue and blue-red capsules in question served several functions:
many elderly patients associate color with therapeutic eﬀect; some patients commingle medications
in a container and rely on color to diﬀerentiate one from another; colors are of some, if limited,
help in identifying drugs in emergency situations; and use of the same color for brand name drugs
and their generic equivalents helps avoid confusion on the part of those responsible for dispensing
drugs.59
The Supreme Court struck down the Second Circuit’s reversal of the district court decision, preserving this
approach to functionality. However, the court actually decided on a technicality - that the Second Circuit
had overstepped its bounds by reversing without establishing that the lower court’s ruling was “clearly
erroneous.”60The Supreme Court did not contribute additional commentary on the subject of functionality,
allowing the lowest court’s holding to remain unmodiﬁed. The Second Circuit followed suit by aﬃrming
without an opinion on remand.61Several years later, in a decision unrelated to pharmaceuticals, the Supreme
Court used a colored capsule’s function of identifying a particular type of medication as a prime example
of functionality potentially barring trademark protection.62Nevertheless, the numerous decisions rejecting
similar assertions of functionality were not reversed, and manufacturers seeking protection should still be
58SK&F v. Premo, 625 F.2d at 1061
60Id.
61Ives Labs., Inc. v. Darby Drug Co., 697 F.2d 291 (2nd Cir. 1982).
62Qualitex, 514 U.S. at 169 (citing Ives, 456 U.S. at 853, 858 n.20).
14able to prevail.
C. Likelihood of Confusion
Beyond the need to determine that the particular trade dress at issue has acquired
secondary meaning and is non-functional, a successful claim of unfair competition requires a proper showing
that there is a likelihood of confusion between the original and the look-alike product. Although courts
generally are willing to ﬁnd that a likelihood of confusion exists if the generic and brand drugs have nearly
identical appearances at the point of purchase, the courts’ ﬁndings have varied for confusion of look-alike
drugs in diﬀerent packaging.
The appearance of the generic must be close to identical to that of the brand version to satisfy the like-
lihood of confusion requirement. In American Home Products v. Barr, the court found no likelihood of
confusion between Advil and an ibuprofen generic because of diﬀerences in shape, sheen, brand imprint,
and overall appearance despite the two tablets’ similar ‘brown’ color.63The facts in this case were “expressly
distinguished” from those in CIBA-GEIGY and SK&F v. Premo, where the only diﬀerence in appearance
was the name printed on the drugs.64In this case, examination of the tablets alone was not expected to
cause consumer confusion.65Similarly, in Florida Breckenridge v. Solvay Pharmaceuticals, the court found
the two versions of estrogen-androgen supplement to have only a “low level of similarity”: whereas the brand
name capsule is described as one-half of an inch long, smooth, glossy, rounded and green, with dark/light
63American Home Products v. Barr, 656 F. Supp. at 1063-1064, 1070.
64Id. at 1071.
65Id. at 1071.
15for diﬀerent dosages, the generic is ﬁve-eighths of an inch long, rough, dull, squared and green, with shade
varying similarly per dosage.66Finding this to be a noticeable diﬀerence and ensuing confusion to be unlikely,
the court denied a motion for a preliminary injunction against the generic manufacturer and later granted a
motion for summary judgment in favor of the alleged look-alike.67
If the only distinguishing factor between the brand name and generic pharmaceutical is the manufacturer’s
label on the bottle or the manufacturer’s name stamped on the particular pills, courts have discounted
the diﬀerences. The Ninth Circuit has held that diﬀerent labels on bottles containing otherwise identical
medications did not suﬃciently minimize the likelihood of confusion.68With respect to the name imprinted
on the medication itself, the Third Circuit upheld a district court decision that this minor diﬀerence did not
mitigate the confusingly similar appearances of the capsules in question.69The court focused on the “overall
physical appearance” and noted that as most of the drug’s consumers were over sixty years old, they would
be unlikely to see clearly enough to distinguish the two products by name.70In McNeil, the diﬀerent imprints
on the parties’ capsules did not suﬃciently diﬀerentiate the two because the writing on the generic drug was
diﬃcult to see – regardless of the patients’ ages.71The court bolstered this holding, noting that “the fact that
the Tylenol product says ‘Tylenol’ does not mean that one preparing to ingest the [generic] capsule would
know it is not Tylenol.”72Finally, the court considered “confusion surveys” and found that “‘net’ confusion
66Florida Breckenridge, 1997 U.S. Dist. LEXIS 17574, at *18-19.
67Id. at *30; Florida Breckenridge, Inc. v. Solvay Pharm., Inc., U.S. Dist. LEXIS 14742, at *17-18 (S.D. Fla. 1998).
68Ross-Whitney Corp., 207 F.2d at 196-197.
69CIBA-GEIGY, 747 F.2d at 851 (citing CIBA-GEIGY, 547 F. Supp. at 1103).
70Id.
71McNeil, 919 F. Supp. at 202.
72Id.
16level[s]” of twenty-eight and twenty-one percent satisﬁed the showing for a likelihood of confusion.73
Courts have, however, produced inconsistent rulings on the proper time – point of purchase versus point of
consumption – for considering the likelihood of confusion.74Where courts have been sympathetic to point
of purchase advocates, brand name manufacturers often lose. In Norwich, the Second Circuit used the
point of purchase as the reference point and subsequently found no possibility for confusion between the
brand name and generic version.75Even though the generic pink liquid medication was “virtually identical
to Pepto-Bismol,” the court found the diﬀerences in bottle shapes, bottle cap appearances, and colors on
the labels to be so great that “it stretches the credulity to imagine a purchaser confusing these disparate
articles.”76Moreover, Smithkline Beckman v. Pennex Products held that the analysis of likelihood of con-
fusion should focus on the purchase point, reasoning that a buyer cannot be confused if the product as a
whole he or she is purchasing looks, at this time of purchase, completely diﬀerent from that of the name
brand.77Consequently, the court found that a likelihood of confusion existed where one defendant-generic
manufacturer sold tablets identical to the brand name originals in translucent bottle, but rejected this claim
against another defendant whose tablets came in a non-translucent bottle, packaged in a box.78 In contrast,
73Id. The court also looked to other circuit courts that took into account confusion surveys with even lower levels of confusion.
McNeil, 919 F. Supp. at 202-203 (citing Mutual of Omaha Ins. Co. v. Novak, 836 F.2d 397, 400 (8th Cir. 1987) (ﬁnding that
a survey showing a confusion level of approximately 10% should be given substantial weight); Exxon Corp. v. Texas Motor
Exchange, 628 F.2d 500, 507 (5th Cir. 1980) (noting that survey results of 15-23% confusion levels are strong evidence in favor
of a ﬁnding of a likelihood of confusion). Moreover, other circuit courts have ruled similarly. See, e.g., James Burrough, Ltd.
v. Sign of Beefeater, Inc., 540 F.2d 266 (7th Cir. 1976) (ﬁnding a 15% level to be evidence of confusion).
74The debate over timing with respect to purchasing the pharmaceutical pertains only to cases of over-the-counter, “OTC,”
drugs since pharmacists rather than consumers have sole access to the original product packages for prescription medication.
See, e.g., Smithkline Beckman Corp. v. Pennex Products Co., 605 F. Supp. 746, 752 (E.D. Pa. 1985) (noting that prescription
drugs are a “unique commodity” which “cannot be compared side by side with another product. This is contrasted with shelf
medication which can be compared ...and comes in many unique packaging conﬁgurations which help indicate the source of
the product”).
75Norwich, 271 F.2d at 571-572.
76Id. at 570, 571.
77Smithkline Beckman, 605 F. Supp. at 751.
78Id. at 751-752.
17other courts consider assertions of confusion from the post-purchase vantage point. American Home Products
v. Chelsea conﬁrmed the viability of actions based on post-purchase confusion.79The court distinguished
its ﬁndings from Smithkline Beckman by pointing out that the plaintiﬀs in the case at bar blame all con-
fusion on the similarity in color while the plaintiﬀs in Smithkline Beckman primarily attributed confusion
to the wide-spread misconception that name brand manufacturers produced their own generic versions, as
well.80However, the court also advanced a more powerful argument for refusing to follow the holding in
Smithkline Beckman:
I can see no reason in law or fact why, in an age of skilled and subtle techniques for marketing
consumer products and winning new customers, courts should refuse to take cognizance of unfair
competitive practices which work themselves out over two, three or more experiences with a product,
rather than quickly, at the moment a consumer ﬁrst sees two opposing products on a shelf and reaches
for only one of them.81
Consequently, the court rejected the argument that product packaging should be factored into trade dress
considerations, noting that some consumers were likely to see the tablets without packaging and, at this
point, the diﬀerence in packaging would have no eﬀect on the likelihood of confusion between the brand
name and generic alternative.82The potential for post-purchase confusion was also acknowledged in McNeil,
where the court focused on the similarity of the red and yellow Tylenol and generic capsules and did not
mention the packaging for the drugs in question.83The court’s conclusion was also based on brand’s assertion
that post-purchase confusion can occur in the realm of OTC analgesics and the court’s acceptance of the
brand’s confusion surveys.84
79American Home Products v. Chelsea, 656 F. Supp. at 1069.
80Id. at 1069.
82Id. at 1071.
83McNeil, 919 F. Supp. at 203.
84Id.
18D. Vicarious Liability
The Lanham Act §43(a) also proscribes unfair competition through passing oﬀ. Generic manufacturers cannot
‘pass oﬀ’ their products as those of the brand name directly, nor can they encourage pharmacists to ‘pass
oﬀ’ generics as name brand drugs to unknowing consumers. As pharmacists are more knowledgeable than
average consumers and more aware of the medications’ sources, the deception usually occurs in the latter
situation. Dating back to 1924, the Supreme Court stated that even though the manufacturer did not dupe the
retailers, the “wrong was in designedly enabling the dealers” to deceive the customers.85While the Supreme
Court has adopted a more stringent standard for ﬁnding vicarious liability than the relatively low standard
of proof used by many lower courts, this avenue of protection remains available to brand manufacturers
seeking trade dress protection.
Findings of passing oﬀ have often been based on evidence of substitutions unauthorized by the consumer,
along with inferences that agents of the generic manufacturer encouraged the pharmacist to take such action.
In William R. Warner & Co., the Supreme Court based its ﬁnding of passing oﬀ both on actual instances
of passing oﬀ to consumers as well as its belief - despite conﬂicting testimony - that agents selling the
generic product induced substitution either directly or simply by suggestion.86However, evidence of actual
substitution is not necessary to prove palming oﬀ. Ruling that passing oﬀ had occurred, the court in SK&F
v. Clark & Clark focused on the “feasibility of substitution,” which, the court believed, was suggested to the
pharmacists by salesmen working for the generic manufacturer.87That the manufacturer was responsible for
planting this idea was inferred from evidence showing that the sales representatives emphasized the similar
85William R.Warner & Co., 265 U.S. at 530.
86Id.
87SK&F v. Clarke & Clarke, 157 F.2d at 731.
19identities of the drugs and the potential for increased proﬁt should the generic be sold in place of the brand
name product.88SK&F v. Heart found that there was no explanation for imitating the brand name product’s
design other than to induce fraudulent substitution by pharmacists.89The court thus held that advertisements
to pharmacists showing the drug’s shape, describing the drug’s color, and touting the low price of the generic
constituted suﬃcient evidence of inducement.90 Some courts have gone even further, holding manufacturers
of generics with identical trade dress to be almost automatically responsible for any substitution that occurs.
Hoﬀman-La Roche held the generic manufacturer liable for passing oﬀ as a direct result of copying the brand
name appearance without addressing allegations of misconduct by defendant’s sales agents.91According to
the court, by producing look-alike generics, the manufacturer “has tossed the lighted squib, it has deliberately
provided the means for deception” and “[i]t would be obliged, if it wished to compete, to do so by employing
a distinctive trade dress of its own, as diﬀerent as possible from Roche’s.”92Intent to encourage substitution
was also inferred in Pennwalt where the generic manufacturer’s adoption of brand name product design was
deemed the “supporting keystone which transforms these circumstances into an ediﬁce for deception,” and
evidence of actual illegal substitutions merely bolstered this foregone conclusion.93Consequently, copying the
trade dress can result in a type of strict liability standard for passing oﬀ claims.
Marion Laboratories rejected the claim of passing oﬀ, however, despite the generic drug’s identical appearance
88Id.
89SK&F v. Heart, 90 F. Supp. 976, 978 (S.D.N.Y. 1950).
90Id.; see also Boehringer Ingelheim, 532 F. Supp. at 1052 (noting that “[b]y drawing attention to the comparability of
the product and the identity of colors, defendants have made drug wholesalers and pharmacist buyers of generic dipyridamole
aware that the customer can be surreptitiously given their less expensive generic product in the place of the more costly [brand
name] Persantine”); A.H. Robbins Co. v. Med. Chest Corp., 1980 U.S. Dist. LEXIS 14412, at *12 (E.D. Mo. 1980) (listing
factors including intentionally copying appearance, drawing attention to the mimicked color of the generic, and emphasizing
the diﬀerence in price in ﬁnding that the look-alike manufacturer knew or should have known that the generics were illegally
substituted for the brand drug).
91Hoﬀman-La Roche, 1980 U.S. Dist. LEXIS 16851, at *31-37.
92Id. at *37.
93Pennwalt, 472 F. Supp. at 420 (analyzing the facts with respect to state unfair competition claims).
20to the brand name product.94With no proof of actual substitutions or salesman misconduct and with generic
promotional materials that referred only to the brand name and not the appearance of the generic in question,
evidence of passing oﬀ was found to be lacking.95 Look-alike manufacturers may also be held liable for
contributory infringement, where pharmacists illegally substitute the generic pharmaceutical for the name
brand.96However, this claim has been advanced only in Inwood Laboratories where it was unsuccessful.97In
this case, evidence that probably would have been suﬃcient to prove passing oﬀ was deemed not enough
to implicate the generic manufacturer for contributory infringement.98The Supreme Court reinstated the
district court’s ﬁndings that pharmacist catalogs containing comparisons of price and information on the
look-alike’s appearance “could not ‘be fairly read’ to encourage infringement.”99In his concurrence, Justice
White singled out pharmaceuticals as a ﬁeld where stringent requirements for contributory infringement are
especially important so that customers can take look-alike generic drugs.100 Although it is possible that
Inwood’s holding could aﬀect the standard for §43 passing oﬀ claims, no court has applied Inwood in this
fashion. The Third Circuit in CIBA-GEIGY declined to answer this question.101Instead, the court simply
distinguished the facts from those in Inwood, emphasizing that the trial court in the case at bar found that
at least one of the motivations for copying the brand’s trade dress was to induce illegal substitution.102The
94Marion Labs., 338 F. Supp. at 769-770. The court also rejected assertions that color of the brand name pharmaceutical
had acquired secondary meaning, and thus the plaintiﬀ lost on both theories of unfair competition. Id. at 768-769.
95Id.
9615 USC § 1114 (2002).
97Inwood Labs., 456 U.S. at 851-853.
98Id.; Cf. SK&F v. Heart, 90 F. Supp. at 978; Boehringer Ingelheim, 532 F. Supp. at 1052; A.H. Robbins, 1980 U.S. Dist.
LEXIS 14412, at *12.
99Inwood Labs., 456 U.S. at 852 (citing Ives Labs., 488 F. Supp. at 397).
100Id. at 861; But see supra notes 121 – 124 and accompanying text.
101CIBA-GEIGY, 747 F.2d at 854.
102Id.
21Supreme Court declined to hear CIBA-GEIGY,103and thus, at the moment, courts are not bound to this
more stringent standard for passing oﬀ.104
E. Equitable Relief
A brand name manufacturer must overcome a few additional hurdles to win an injunction preventing generic
drugs from being distributed with the same product design. The original distributor can seek a preliminary
injunction before trial and a permanent injunction at trial to prevent the opposing party from selling generic
versions in the same color, shape, texture or any other distinctive feature as the brand name medication:
The several courts vested with jurisdiction of civil actions arising under this Act shall have power
to grant injunctions, according to the principles of equity and upon such terms as the court may
deem reasonable, to prevent the violation of any right of the registrant of a mark registered in the
Patent and Trademark Oﬃce or to prevent a violation under subsection (a), (c), or (d) of section
43 [15 USCS § 1125].105
For preliminary injunctions, courts have interpreted this mandate to require a showing beyond a likelihood of
success on the merits that the movant would be irreparably harmed without an injunction, that the balance
of equities weighs in favor of the movant, and that the public would be best served by such an injunction.
103Bolar Pharm. Co., Inc. v. CIBA-GEIGY Corp., 471 U.S. 1137 (1985).
104It should be noted, however, that an article in the National Law Journal criticized the CIBA-GEIGY ruling and advocated
for the adoption of the more stringent standard: “First, if ‘reasonable anticipation’ continues to be a viable standard under
Sec. 43(a), then the Supreme Court’s decision in Ives [Inwood] is meaningless; future litigants simply will rely on Sec. 43(a)
and obtain relief under a legal standard that the Supreme Court questioned in Ives. Second, it is apparent that the ‘reasonable
anticipation’ standard virtually guarantees a violation of Sec. 43(a) whenever there has been copying since one can always
‘reasonably’ anticipate that some unscrupulous merchants will attempt to enhance their proﬁts by passing oﬀ a less expensive
generic product for costlier goods.” Kenneth A. Plevan & Miriam L. Siroky, The 3d Circuit Gets a Dose of Suits Filed against
‘Look-Alike’ Drugs, Nat’l L. J., Aug. 12, 1985, at 22.
221. Irreparable Harm
Courts have accepted claims of irreparable harm based on ﬁnancial loss, vulnerability to product liability
suits for which another manufacturer may be at fault, and damage to goodwill. Such ﬁndings do not
require the party seeking the injunction to show actual evidence of lost sales due to trade dress infringement.
Illegal substitutions are unlikely to be discovered as pharmacists are not expected to turn themselves in for
committing an illegal action and patients are probably unaware of the switch given the close resemblance of
the generic to the brand name medication. This led the district court in Par Pharmaceuticals to order an
injunction and declare it “impossible” for the movant to calculate the full extent of the ﬁscal loss on account
of such substitutions.106The court also noted that condoning the use of generic look-alikes would impose an
additional cost on the brand manufacturer of informing interested parties that it is not the sole manufacturer
of a particular drug in a particular trade dress.107
Courts have also accepted the argument that since generic look-alikes are virtually indistinguishable from
name brand drugs, the manufacturer risks being held responsible should a consumer have a bad reaction to
a substituted generic.108Any bad experience a consumer has with a drug, which he or she believes to be the
brand name, but is actually the identical generic, can cause irreparable damage to the brand’s reputation
and goodwill.109Moreover, if a product liability lawsuit resulted:
106Par Pharm., 1985 U.S. Dist. LEXIS 16648, at *15.
107Id.
108SK&F v. Premo, 625 F. 2d at 1066.
109See McNeil-PPC, 919 F. Supp. at 204; Pennwalt, 472 F. Supp. at 421.
23the striking similarity in appearance of the two products would make it unlikely that [the brand
manufacturer], the deep pocket defendant, could prove that the harm was caused instead by [generic]
capsules, because the only proof as to the source would be the capsules themselves, long since digested
by the patient.110
The court thus deemed this risk, along with the acknowledgement that lost sales would be diﬃcult to
quantify, suﬃcient to show that the movant could be irreparably harmed if the distribution of generic look-
alike capsules continued.111
2. Balance of Equity
Once a court concludes that a claim of unfair competition has been proven, the balance of equity generally
tips in favor of the brand name manufacturer who is allegedly suﬀering from unfair competition.112After
rejecting the assertions that the brand drug’s trade dress was functional and that copying the trade dress
enabled the generic manufacture to compete more eﬀectively, the Third Circuit in SK&F v. Premo described
a record “almost totally devoid of equities” in favor of the generic manufacturer.113Declaring that trade dress
appropriation did not have “the look, sound or feel of equity,” the court upheld a ﬁnding that the balance
tipped in favor of the movant.114 Other courts have considered the generic manufacturer’s claims of ﬁnancial
injury should an injunction be granted, but the asserted beneﬁts of the injunction often prevail. Pennwalt
111See also American Home Products v. Chelsea, 572 F. Supp. at 286; CIBA-GEIGY, 547 F. Supp. at 1116, Hoﬀman-La
Roche, 1980 U.S. Dist. LEXIS 16851, at *41; Boehringer Ingelheim, 532 F. Supp. at 1065.
112In considering a permanent injunction, the U.S. Supreme Court found that the balance of equities weighed
against the injunction despite a ﬁnding of unfair competition. Holding an injunction to be excessive, the court
instead required the generic manufacturer to label its product distinctively and to include a notice on the
label that this product is not to be confused with that of the name brand. William R. Warner & Co., 265 U.S. at
532-533.
113SK&F v. Premo, 625 F.2d at 1066-1067; see also CIBA-GEIGY, 547 F. Supp. at 1116; Par Pharm., 1985 U.S. Dist. LEXIS
16648, at *16; Hoﬀman-La Roche, 1980 U.S. Dist LEXIS 16851, at *42; Boehringer Ingelheim, 532 F. Supp, at 1065-1066.
114Id.
24described weighing the competing equity interests as an attempt to “balance the interest in free competition
against the interest in securing to businesses the fruits of their initiative and enterprise.”115That the drugs
in question were not bioequivalent bolstered the case against the generic manufacturer as the injunction
would prevent illegal substitutions of such generics from going undetected.116The court added that the
injunction would deter pharmacists from making illegal substitutions, especially since the governing law on
substitution was deemed unclear.117Moreover, since the generic manufacturer currently oﬀers a version of the
same generic in diﬀerent colors, the threat to ‘free competition’ is tempered as well.118An injunction’s harm
to the generic manufacturer was also discounted in McNeil, where the court noted that the manufacturer
deliberately copied the brand’s trade dress and thus any subsequent harm caused by an injunction would be
due to it’s “own making.”119
3. Public Interest
Several courts have found that trade dress protection serves the over-arching public interest as well. That
generic look-alikes may actually diﬀer in eﬃcacy or absorption rates120from the original presents a strong
public policy argument for enforcing trade dress protection of name brand medication. In American Home
Products v. Chelsea, the court distinguished prescription medication from all other items as a ﬁeld where
trade dress protection is of utmost importance; when dealing with pharmaceuticals, substitution of look-alike




119McNeil-PPC, 919 F. Supp. at 204.
120See SK&F v. Premo, 625 F.2d at 1061; American Home Products v. Chelsea, 572 F. Supp. at 281.
25generics harms not only the brand manufacturer from a decrease in sales but also the patient from ingesting
a drug of potentially less quality or having a diﬀerent rate of absorption in the body.121The court concluded
that “[f]rom a public interest point of view, the risk of harm to the patient stands highest on the scale,”
thus strengthening the case against generics with the same appearance.122Where the generic medication
in question was not bioequivalent, the Third Circuit similarly called the public interest in preventing such
generics from appearing identical to the brand name version to be a “a highly signiﬁcant factor favoring
pendente lite relief.”123In the end, precluding the manufacture of look-alike generics better protects against
illicit substitutions of pharmaceuticals, than policing individual pharmacists. An article in the Trademark
Reporter noted that, an “old saw advises that we ‘lock our barn doors and keep our neighbors honest’; trade-
mark registration is the best lock available.”124 Trade dress protection can also be viewed as pro-competitive.
Deeming shortsighted the assertion that look-alike generics force brand manufacturers to compete, the Third
Circuit posited that in the long run, encouraging companies to maintain brand recognition would beneﬁt
society:
The adoption of a distinctive trade dress as a means of identifying a product with its source is a legit-
imate means for the promotion of the user’s business, and permitting piracy of that identifying trade
dress can only discourage other manufacturers from making a similar individual promotional eﬀort.
Moreover, allowing a manufacturer to be able to acquire and maintain a reputation for consistent
good quality is certainly pro-competitive. Permitting a business climate in which substitution of
products over which the ﬁrst manufacturer has no quality control in the long run can only discourage
the eﬀort to compete on the basis of reputation for quality.125
As brand manufacturers have no control over the quality of the generic drugs, permitting the existence of
virtually indistinguishable generics lessens a brand’s incentives to promote the brand and to maintain high
121American Home Products v. Chelsea, 572 F. Supp. at 281.
122Id.
123SK& F v. Premo, 625 F.2d at 1067.
124Iver P. Cooper, Trademark Aspects of Pharmaceutical Product Design, 70 Trademark Rep. 1, 46 (Jan. – Feb., 1980).
26quality standards. Generic look-alikes can be thus considered detrimental to the community.
III.
Trademark Protection of Color Alone
Along with trade dress protection for pharmaceutical product design as a whole, brand name pharmaceu-
ticals can obtain trademark registrations for individual features of the design, such as color. Trademark
infringement falls under the general rubric of unfair competition.126The diﬀerence between trademark and
trade dress is that trade dress involves the overall marketing scheme, whereas a trademark focuses only
on a particular symbol of the product’s source.127Trademark protection oﬀers additional beneﬁts, including
the right to bar importation of confusingly similar goods, constructive notice of mark ownership, the op-
portunity for incontestable status, and prima facie evidence of trademark validity and ownership.128Both
trademark and trade dress infringement suits require a showing of secondary meaning,129non-functionality,
and a likelihood of confusion.130Although the standards for secondary meaning and functionality are virtu-
ally interchangeable,131courts have wrestled with the idea of requiring a higher standard for the likelihood
of confusion for color trademarks. Historically, courts resisted granting trademark protection for a color
126See Deere & Co. v. Farmhand, Inc., 560 F. Supp. 85, 94 (S.D. Iowa 1982), aﬀ’d, 721 F.2d 253 (8th Cir. 1983) (referring
to McCarthy, Trademarks and Unfair Competition, sec. 2:2 (1973) and reports on the bill that became the Lanham Act S.R.
1333, 79th Cong. 2d sess. (1946)).
127Deere, 560 F. Supp. at 94.
128See Qualitex, 514 U.S. at 174 (citing 15 U.S.C. §1124, §1072, §1065, §1057(b).
129A showing of secondary meaning is required unless the mark is deemed inherently distinctive. See infra Part IV.A.
130Id. at 95 (citing Truck Equipment Service Co. v. Fruehauf Corp., 536 F.2d 1210 (8th Cir. 1976); see also Vaughan Mfg
Co. v. Brikam Int’l, Inc. 814 F.2d 346, 348 n.2 (7th Cir. 1986).
131Vaughan Mfg. Co., 814 F.2d at 348 n.2.
27by itself, but the Supreme Court turned the tides in Qualitex v. Jacobson Products.132This watershed case
has not been speciﬁcally interpreted in the context of pharmaceuticals, but the ruling nevertheless supports
brand manufacturers’ right to protect individual aspects of product designs.
A. The Traditional Rule
Traditionally, color, per se, could not receive trademark protection. Years before the Lanham Act was in-
troduced in 1946, the Supreme Court noted in dicta that “you cannot register a mark of which the only dis-
tinction is the use of a color....”133As a result, there was a general prohibition on registering colors.134After
the enactment of the Lanham Act in 1946, the notion that color alone could not be protected from copying
remained, even though no such bar was explicitly stated.135The Act deﬁned a “trademark” as “any word,
name, symbol, or device, or any combination thereof ...”136– which could certainly include a color – and
delineated a set of unregistrable items137– which did not mention color. However, many courts followed
Leschen instead of looking to the new legislation.
The post-Lanham Act rejection of color alone trademarks was partly based on resistance to change. In
132Qualitex, 514 U.S. at 174 (1995).
133Leschen & Sons Rope Co. v. Broderich & Bascom Rope Co., 201 U.S. 166, 172 (1906) (quoting In re Hanson’s Trade-mark,
37 Ch. D. 112, 116 (1887)).
134See, e.g., In re Gen. Petroleum Corp of California, 18 C.C.P.A. 1444 (CCPA 1931) (rejecting a trademark application for
violet gasoline); In re Sec. Eng’g Co., Inc., 27 C.C.P.A. 1389 (CCPA 1940) (denying protection for blue-and-aluminum oil well
reamers).
135See 15 U.S.C. 1051-1127 (1988 & Supp. V 1993).
13615 U.S.C. 1127 (1988 & Supp. V 1993).
13715 U.S.C. 1052 (1988 & Supp. V 1993).
28Campbell Soup Co. v. Armour & Co., the Third Circuit simply proclaimed “[t]hat a man cannot acquire a
trade-mark by color alone has been stated a good many times in decisions and textbooks” without giving
any thought to protectability of the colors at issue.138Similarly, in denying protection to the pastel blue
of “Equal” sugar substitute packets, the Seventh Circuit chose to maintain the status quo in barring color
alone protection, noting that “[c]onsistency and predictability of the law are compelling reasons for not
lightly setting aside a settled principled of law.”139The court declared that there was “no need” to bring
about change.140 Along with an aversion to change, courts advanced theoretical arguments against the
protection of color per se. For example, the color depletion theory assumes that the supply of colors for mar-
ketable products is limited, and critics of color alone protection assert that if individual brands win exclusive
rights to sell products in designated colors, the supply of available colors for competing manufacturers will
diminish until no colors are left.141Dating back to 1906, the Sixth Circuit expressed this belief, claiming that
the only available colors were primary colors as well as black and white.142In the debate over protection
of the red and white Campbell Soup labels, the Third Circuit worried that if successful, “they may thus
monopolize red in all of its shades[,] the next manufacturer may monopolize orange in all its shades and the
next yellow in the same way. Obviously, the list of colors will soon run out.”143Others have argued that the
supply will be further reduced because certain colors are not marketable to consumers:
138Campbell Soup Co. v. Armour & Co., 175 F.2d 795, 798 (3rd Cir. 1949) (citing Leschen, 201 U.S. 166; Samson Cordage
Works v. Puritan Cordage Mills, 211 F. 603 (6th Cir. 1914); James Heddon’s Sons v. Millsite Steel & Wire Works, 128 F.2d 6
(6th Cir. 1942); 1 Nims, Unfair Competition and Trade-Marks §210b; 2 Callmann, Unfair Competition and Trade Marks sec.
§71.5 (1945).
139NutraSweet Co. v. Stadt Corp., 917 F.2d 1024, 1027 (8th Cir. 1990).
140Id.
141See James L. Vana, Color Trademarks, 7 Tex. Intell. Prop. L.J. 387, 388-389 (Spring, 1999); Jean Hayes Kearns,
Comment: Qualitex Co. v. Jacobson Products Co.: Orange You Sorry the Supreme Court Protected Color?, 70 St. John’s
L. Rev. 337, 353-357 (Spring, 1996).
142Diamond Match Co. v. Saginaw Match Co., 142 F. 727, 729 (6th Cir. 1906); see also Paciﬁc Coast Condensed Milk Co.
v. Frye & Co., 85 Wash. 133, 147 (1915) (noting that “the primary colors are few...”).
143Campbell Soup, 175 F. 2d at 798.
29By the time one discards colors that, say, for reasons of customer appeal, are not usable, and adds
the shades that competitors cannot use lest they risk infringing a similar registered shade, then one
is left with only a handful of possible colors.144
Accordingly, if the supply is so limited, and if every market player acts to secure an identiﬁable color for its
product, entrants to the market will face increasing diﬃculty in competing eﬀectively.145Seeking protection
for its blue sugar substitute packets, NutraSweet pushed for the adoption of a case-by-case analysis, where
the court would allow protection only after determining that there was no “competitive need” for the color
to remain available to competitors.146However, the court dismissed this suggestion as “unworkable” and
maintained it could not foresee the needs of future competitors.147
Critics of color per se protection also point to the diﬃculties of shade confusion to support their position.
Shade confusion is premised on the notion that courts and the Trademark Trial & Appeal Board (T.T.A.B.)
148donothavetheexpertisetocomparecolorsanddeterminethelikelihoodofconsumerconfusion.149Courts have thus refused to
grant protection in part because of their “desire that infringement actions not denigrate into questions
of shade confusion.”150The comparison of colors is ostensibly more complex than the comparison of the
sounds of words and phrases because a color’s appearance can be altered by the light under which it is
145Id. The registration of a color will not necessarily prevent another manufacturer from using this color for a diﬀerent product,
as long as there is not close “proximity of the products.” Karin S. Schwartz, It Had to be Hue: The Meaning of Color “Pure
and Simple,” 6 Fordham Intell. Prop. Media & Ent. L.J. 59, 76-77 (Fall, 1995) (citing the standard established in Polaroid
Corp. v. Polorad Elecs., Corp., 287 F.2d 492, 495 (2nd Cir. 1961), cert denied, 368 U.S. 820 (1961)).
146NutraSweet, 917 F.2d at 1027.
147Id.
148The T.T.A.B. reviews contested trademark registrations.
149See Vana, supra note 141, at 389; Kearns, supra note 141, at 346-353.
150W.H. Brady Co. v. Lem Prods., Inc., 659 F. Supp. 1355 (N.D. Ill. 1987); see also In re Owens-Corning Fiberglas Corp.,
774 F.2d 1116, 1131 (Fed. Cir. 1985) (dissent echoing the same shade confusion argument); NutraSweet, 917 F.2d at 1027
(declining to assume responsibility for determining just how diﬀerent colors must be to avoid a likelihood of confusion).
30viewed.151Moreover, the juxtaposition of two colors can arguably change a color’s appearance.152Finally,
shade confusion devotees have maintained that since color perception is subjective, competitors will have to
avoid the entire range of shades of a protected color to prevent litigation.153
B. Challenge of the Traditional Rule
In 1985, the Federal Circuit decided Owens-Corning Fiberglas Corp. and was the ﬁrst circuit court to
recognize trademark protection for a color.154This appeal arose out of a T.T.A.B. ruling that while an overall
color could receive trademark protection, the color “pink” for ﬁbrous glass residential insulation was denied
registration due to an insuﬃcient showing of the color’s distinctiveness.155The Federal Circuit conﬁrmed the
lower court’s ruling that color alone was worthy of protection and reversed the T.T.A.B., ﬁnding the evidence
of a public association of the mark with the manufacturer to be more than suﬃcient.156 Most importantly,
Owens-Corning categorically rejected all of the arguments used by opponents of trademark protection for
colors. As a general matter, the court likened over-all color to over-all surface design, which was eligible for
151Kearns, supra note 141, at 349-350; see also Qualitex, 514 U.S. at 167 (referencing respondent’s assertion that lighting such
as “morning sun, twilight mist” can change perceptions of color).
152Kearns, supra note 141, at 349-350 (citing evidence that a green item on a red shelf appears diﬀerent from a green item on
a grey shelf).
153Id. at 350-352.
154See Owens-Corning Fiberglas Corp., 774 F.2d at 1118.
155In re Owens-Corning Fiberglas Corp., 221 U.S.P.Q. (BNA) 1195, 1199 (T.T.A.B. 1984).
156Owens-Corning Fiberglas Corp., 774 F.2d at 118-1123, 1127.
31protection.157The court also rejected all of the theoretical arguments against registering color alone. The
color depletion theory was referred to as an “‘unreasonable restriction on the acquisition of trademark
rights,”’ since the practice of dying such ﬁberglass was uncommon and unlikely to hinder competition
in the industry.158The court also followed the lower court’s rejection of the shade confusion argument,
noting that the requisite likelihood of confusion analysis between shades would be no more taxing on the
judiciary than the current likelihood of confusion among diﬀerent words.159Consequently, since the color pink
served no function other than identifying the brand of the insulation, it was deemed deserving of trademark
protection.160 The Eighth Circuit soon followed suit in Master Distributors, Inc. v. Pako Corp., declining
to adopt an absolute prohibition against color alone protection.161The court adopted the Federal Circuit’s
interpretation of the Lanham Act, noting that the bounds of trademark protection did not exclude color
marks.162Unlike color protection opponents who felt that preventing protection and honoring precedent were
crucial to the stability of the system, the court posited that barring such protection would actually lead to
“confusion and inconsistency.”163The Eighth Circuit rejected the color depletion argument pointing out that
the spectrum of available colors is indeed much larger than the limited palette of primary colors; a color atlas
listed 1,266 colors and the National Bureau of Standards acknowledged 267 hues.164Masters Distributors also
157Id. at 1122-1123 (citing In re Todd Co., 290 F.2d 597, 600 (CCPA 1961) (accepting the registration of a pattern of green
parallel lines for safety paper products); Vuitton et Fils S.A. v. J. Young Enterprises, Inc., 644 F.2d 769, 775 (9th Cir. 1981)
(allowing an overall pattern of ﬂorets and letters to receive trademark protection).
158Id. at 1122 (citing Owens-Corning Fiberglas Corp., 221 U.S.P.Q. at 1198).
159Id. at 1123 (citing Owens-Corning Fiberglas Corp., 221 U.S.P.Q. at 1198).
160Id. at 1123, 1128.
161Master Distributors, Inc. v. Pako Corp., 986 F.2d 219, 224 (8th Cir. 1993).
162Id. (citing Owens-Corning Fiberglas Corp., 774 F.2d at 1119).
163Id.
164Id. at 223 (referring to A. Kornerup & J.H. Wanscher, Color Atlas 7 (1961); Kenneth L. Kelly & Deane B. Judd, Color:
Universal Language and Dictionary of Names 4 (1976)).
32emphasized that color protection extended only to a particular shade of a color, thus no manufacturer would
be receiving the right to “monopolize red ‘in all its shades.”’165While the court conceded that color protection
might require the judiciary to confront shade confusion problems, it maintained that the determination of
a likelihood of confusion among colors was no more taxing than that for any other type of mark.166Since
several courts had already dealt with shade confusion problems and since experts could aid the court in
diﬀerentiating between colors, the court was unmoved by the argument that color mark infringement cases
would be more complex. 167
C. The Supreme Court Speaks: Traditional Rule Abolished
The Federal Circuit’s innovative rationale in Owens-Corning was rejected by the Seventh Circuit but adopted
by the Eighth Circuit,168and the Supreme Court soon agreed to resolve the circuit split. In 1995, Qualitex v.
Jacobson Products ended the color per se controversy, holding that there is no absolute bar to trademarking
color alone.169Qualitex deemed the green-gold color for dry cleaning press pads, which had acquired suﬃcient
165Id. at 223 (disagreeing with the ramiﬁcations of color protection in Campbell Soup, 175 F.2d at 798).
166Id. at 223-224.
167Id. at 223-224 (referencing In re Hodes-Lange Corp., 167 U.S.P.Q. 255 (T.T.A.B. 1987) (weighing a “brilliant yellow” band
versus a “bronzy gold” band); Amsted Indus., Inc v. West Coast Wire Rope & Rigging, Inc., 2 U.S.P.Q. 1755 (T.T.A.B. 1987)
(comparing two strands of “yellow” wire rope to two strands of “yellow and yellowish-green”).
168Cf. NutraSweet, 917 F.2d at 1027 (citing Owens-Corning Fiberglas Corp., 774 F.2d at 1128) (sympathizing with the
dissent’s assertion that “the overall color of a product cannot be a trade identity designation, nor is it entitled to registration.”)
and Master Distributors, 986 F.2d at 224 (agreeing with Owens-Corning and “declining to establish a per se prohibition against
protecting color alone as a trademark”).
169514 U.S. at 162.
33secondary meaning, to be a source-identifying symbol worthy of trademark protection.170With its unanimous
decision, the Supreme Court sent a strong, clear message: color can and should be trademarked where all
statutory requirements have been met.
As in Owens-Corning and Master Distributors, Qualitex rejected the theoretical arguments against color
alone trademarks. Finding color marks to be no diﬀerent, inherently, than any other type of mark, the court
noted that, “[i]t is the source-distinguishing ability of a mark – not its ontological status as color, shape,
fragrance, word, or sign – that permits it to serve these basic purposes.”171The court’s determination that
color trademarks should not be subjected to a heightened standard of review eﬀectively rejects the color
depletion and shade confusion arguments. Courts cannot consider availability of alternative colors any more
than they worry about the availability of alternative words and the threshold for a likelihood of confusion
must remain the same whether the court is considering shades of colors or word pronunciations.
In Qualitex, the color depletion theory was speciﬁcally dismissed as “unpersuasive” on the basis that the
threat of color scarcity is relatively small.172The theory’s resulting ban on color trademarks simply would
be an alarmist reaction to a rare problem that would anyway be prevented by the non-functionality require-
ment.173In other words, if the exclusive right to use a color mark severely hindered competition because no
other viable colors were available, a color would be seen as a serving a non-trademark function and could
thus fail to receive trademark protection. Under the court-advocated system of case-by-case analysis, rather
than a general prohibition of color trademarks, the presiding court would have authority to deny protection
to any mark which threatened to grant the trademark holder monopoly powers. As for the concern that
courts would not be able to properly assess the likelihood of confusion between shades due to diﬀerences in




34lighting, Qualitex suggested that courts mimic the lighting conditions under which a product is generally
sold.174
IV. Post-Qualitex: Reactions and Ramiﬁcations
Although clearly establishing that color alone can be protected when all other statutory requirements are met,
Qualitex left open to interpretation exactly what these requirements demanded. Consequently, Qualitex has
been widely scrutinized, with courts and legal scholars oﬀering interpretations of the requisite distinctiveness
and functionality, reassertions of the shade confusion theory, as well as hypotheses on the future course of
single-feature, non-traditional trademark doctrine in light of this decision.
A. Secondary Meaning Revisited
The Supreme Court sidestepped the issue of whether or not a color could be inherently distinctive – and
thus not require a showing of secondary meaning.175The court’s acknowledgement that “a product’s color is
unlike “fanciful,” “arbitrary,” or “suggestive” words or designs, which almost automatically tell a customer
174Id. at 167-168 (citing cases where such lighting re-enactments have already been carried out for assessing the likelihood of
confusion for trademarks consisting of a color plus a design).
175Qualitex, 514 U.S. at 169 (noting only that “[w]e cannot ﬁnd in the basic objectives of trademark law any obvious theoretical
objection to the use of color alone as a trademark, where that color has attained ‘secondary meaning’ and therefore identiﬁes
and distinguishes a particular brand ...”).
35that they refer to a brand,” suggests that secondary meaning would be necessary to receive trademark
protection.176Several courts have since read Qualitex to call for a showing of secondary meaning for color
marks,177as has a Senior Examining Attorney with the PTO.178However, no such requirement was explicitly
stated, and at least one scholar has asserted that color alone marks can be inherently distinctive if the use
of the color is suﬃciently unusual.179
B. Aesthetic Functionality
Qualitex also added a new facet to the assessment of a mark’s functionality. Instead of creating an absolute
bar to color marks that serve a non-trademark function, the court noted that:
where a color serves a signiﬁcant nontrademark function – whether to distinguish a heart pill from a
digestive medicine ...– courts will examine whether its use as a mark would permit one competitor
(or a group) to interfere with legitimate (nontrademark-related) competition through actual or
potential exclusive use of an important product ingredient.180
Later, in 2001, the Supreme Court limited the application of the competitive need analysis to cases of
aesthetic functionality.181For all other functions, such as being essential to the product’s use or aﬀecting the
cost or quality of the product, the Inwood standard remains in place.182Consequently, the PTO’s analysis
176Id. at 162-163.
177See Mana Prods., Inc. v. Columbia Cosmetics Mfg., Inc., 65 F.3d 1063, 1071 (2nd Cir. 1995); Fabrication Enters., Inc. v.
Hygenic Corp., 64 F.3d 53, 58 n.3 (2nd Cir. 1995); Forschner Group v. Arrow Trading, 124 F.3d 402 (2nd Cir. 1997); Sazerac
Co. v. Skyy Spirits, Inc., 37 U.S.P.Q.2d (BNA) 1731, 1733 (E.D. La. 1995).
178See Faye M. Hammersley, Comment: The Smell of Success: Trade Dress Protection for Scent Marks, 2 Marq. Intell.
Prop. L. Rev. 105, 143 (1998) (citing a telephone interview with an anonymous Examining Attorney, PTO (Oct. 30, 1997).
179Schwartz, supra note 145, at 94-95 (citing purple peanuts as an example of a disjunctive use of color that could be considered
inherently distinctive); see also Hammersley, supra note 178, at 145 (suggesting that color and scent marks can be viewed as
inherently distinctive if analyzed under trade dress law).
181TrafFix Devices, Inc. v. Mktg. Displays, Inc., 532 U.S. 23, 33 (2001). See infra notes 184-186 and accompanying text.
182Id. (quoting Inwood, 456 U.S. at 850, n. 10); see supra note 59 and accompanying text.
36of an application for registration of a color alone trademark, with an aesthetic function, now includes the
additional determination of whether or not this function would hinder competition.183 Qualitex’s aesthetic
functionality analysis, that protection will be barred for a color functioning only to be aesthetically pleasing if
this color is necessary to compete eﬀectively,184has also been criticized. Although this idea allays fears of color
depletion, the aesthetic functionality doctrine had previously been disfavored among courts.185Consequently,
Qualitex was criticized for “breathing new life into a once dying doctrine,” under which “no trademark holder
can feel safe.”186Others have taken issue with this functionality analysis, claiming that the psychological
eﬀects colors have on consumers are strong, but not easily recognizable by the courts or even the consumers,
themselves.187
C. Shade Confusion Reasserted
Some members of the legal community strongly oppose the court’s rejection of shade confusion, but many
of the revamped theoretical arguments remain unconvincing. One legal scholar reemphasized the concern
183Cf. Vana, supra note 141, at 395 (predicting that “nearly all color applications will require analysis of the ‘competitive
eﬀect’ factor”).
184514 U.S. at 169.
185Daniel C. Huddock, Notes and Comments: Qualitex Co. v. Jacobson Products Co.: Color Receives Trademark Protection
and the Courts Receive Confusion, 16 J.L. & Com. 139, 152 (Fall, 1996) (citing the Third Circuit’s disdain for the doctrine
because “the more appealing the design, the less protection it would receive.” Keene Corp. v. Paraﬂex Industries, Inc., 653
F.2d 822, 825 (3rd Cir. 1981) quoted in 1 J. Thomas McCarthy, McCarthy’s on Trademarks and Unfair Competition §7.26[4][b],
at 7-151).
186Id. at 152, 153.
187See Elizabeth A. Overcamp, Recent Developments: The Qualitex Monster: The Color Trademark Disaster, 2 J. Intell.
Prop. L.J. 595, 616-619 (Spring, 1995). But see supra notes 43-48 and accompanying text.
37over shade confusion, noting that the process of diﬀerentiating between shades of a color is diﬀerent in the
judge’s chamber “where a judge may pore over swatches of color” from the actual purchase situation where
“consumers are often rushed or unwilling to make a detailed analysis of a product’s appearance.”188However,
this same rationale could be applied to any type of likelihood of confusion consideration: perhaps judges
“pore over” the similarity in sounds of two words to a greater extent than does the purchasing public, but
this does not therefore imply that courts should abstain from such analysis. Qualitex’s suggestion that courts
re-create a store’s lighting conditions to portray the color marks more accurately has also been criticized
because store lighting can vary by time of day, type of store, etc.189Again, this critique fails to take into
account that perception of colors, symbols, sounds, is, by nature, subjective. Following this line of reasoning,
courts should decline to determine the likelihood of confusion between words because pronunciations will vary
according to the speaker’s voice and inﬂection. Finally, scholars contend that because trademark registrations
are printed in black and white, with only eight available code linings for colors, courts are likely to be overly
generous in determining the limits on confusingly similar colors.190Yet, courts have managed to consider
color in combination with other features,191where the color registration process is no diﬀerent. There are
also several generally accepted alternative, more descriptive methods of describing color.192In the end, the
assertion that as a result of color alone protection, the “ﬁnder of fact will be laden with subjectivity”193holds
188Huddock, supra note 185, at 149.
189See Overcamp, supra note 187, at 615-616.
190Kearns, supra note 141, at 352-353.
191See, e.g., Mishawaka Rubber & Woolen Mfg Co. v. S.S. Kresge Co., 119 F.2d 316 (6th Cir.), rev’d on other grounds 316
U.S. 302 (1942); Hygienic Products Co. v. Coe, 85 F.2d 264 (D.C. Cir. 1936); Layton Pure Food Co. v. Church & Dwight
Co., 182 F. 24 (8th Cir. 1910); Barbasol Co. v. Jacobs, 160 F.2d 336 (7th Cir. 1947).
192See Cooper, supra note 124, at 5 n.20 (referring to the ISCC-NBS method of designating colors by exact shade, the Munsell
system of describing colors by hue, value, and chroma, and the Ostwald system of specifying colors by hue and color/black/white
content).
193Huddock, supra note 185, at 150.
38no more weight for color marks than for any others.194
D. Scent
The approval of color alone protection under Qualitex should bolster the case for protection of other single-
aspect non-verbal trademarks, such as scent. Before the Supreme Court handed down Qualitex, the T.T.A.B.
accepted the registration of the plumeria scent mark for sewing thread and embroidery yarn, with a suﬃcient
showing of secondary meaning.195The PTO’s recognition of scent marks was limited, precluding protection
for a fragrance that is a main feature of the product in question, such as perfume.196As a protected mark
must create a unique association between the scent and that particular product, a fragrance can be regis-
tered only if it is not normally associated with the item in question.197 Scent marks should be protected
because they are eﬀective source indicators. Studies have shown that the human memory is receptive to
fragrant experiences, but this memory can only be conjured when a smell is re-experienced.198As a result,
“when many people think they are recalling odors, they are actually thinking of ‘some object associated with
an odor...,”’199thus making scents quintessential source-indicators and prime candidates for trademark pro-
tection. Trademark protection is also expected to beneﬁt the public by allowing manufacturers of scented
products to protect their goodwill, prevent free-riding, and reduce consumer search costs for these uniquely
194Interestingly, French law allows for the protection of distinctive shades of color alone marks, including “bright violet rubber
bulbs for automobile horns, sky blue gasoline, antique pink yeast bags, and blue-grey rubber stoppers. Cooper, supra note 124,
at 23.
195In re Celia Clarke, 17 U.S.P.Q.2d (BNA) 1238 (T.T.A.B. 1990).
196Id.
197Hammersley, supra note 178, at 127.
198Id. at 128 (citing Trygg Engen, Odor Sensation and Memory 5 (1991).
199Id.
39recognizable products.200 Although scent mark registrations can be opposed on the grounds of function-
ality, application of the Qualitex holding will demonstrate that such marks can be protected. If a particular
scent is essential to the use of the product, courts will deny protection, but if the scent merely adds aesthetic
appeal, then protection will be precluded only when competition would be impaired signiﬁcantly.201As there
are a plethora of available alternative scents,202trademark protection of an individual scent is unlikely to
hinder competition.
Critics of scent protection may assert versions of the shade confusion argument, but Qualitex’s rejection
of the color arguments should similarly limit their persuasiveness in this context. The lack of an oﬃcial
classiﬁcation system and the subjective nature of scent perception lay the groundwork for a shade confu-
sion argument.203Yet the Qualitex ﬁnding that color marks are no more diﬃcult to analyze than words or
symbols,204renders moot this assertion with respect to scents.205 Despite the newly expansive reach of
trademark protection, registration of scent marks in the U.S. has been scarce. As of 1998, three years after
Qualitex was decided, only eight trademark applications had been ﬁled for scent marks.206Schering-Plough
has considered pursuing common law trademark protection for its unique scent of Coppertone sunscreen, but
it has declined to register this scent.207However, fragrance mark applications are numerous in the United
200Id. at 129.
201See supra notes 180-183 and accompanying text. See also id. at 135-137 (positing that protection of a pine or lemon
scented household cleaning product would hamper competition – and thus be denied protection, whereas a licorice scented
version of the same product would be suﬃciently distinctive that it would not impede on competition).
202See Hammersley, supra note 178, at 138.
203See Hammersley, supra note 178, at 150.
204See supra notes 170-171, 188-194 and accompanying text.
205See Hammersley, supra note 178, at 150.
206Id. at 105, n. 4, 127 (referring to applications for a lemon scent for a digital laser printer; cherry, almond, tutti-frutti,
citrus, bubble gum, and strawberry for fuel additives; and an apple scent for an animal bit).
207Telephone Interview with Joel Wiener, Senior Director, Trademark and Copyrights, Schering-Plough Corp. (Feb. 5, 2003).
40Kingdom, where the Trade Mark Registry is sympathetic to scent protection,208and this trend may soon
catch on in the United States, as well.
D. Flavor Marks
The rising trend of color alone and scent alone marks may also lend credence to the notion that ﬂavor
alone marks should be protected, and distinguishing ﬂavors, as opposed to scents, are likely to be used
by pharmaceutical companies. The Supreme Court precluded protection for chocolate ﬂavored quinine in
1924,209but courts have not revisited this issue since Qualitex. Since the general trend in trademark law
has been to extend the bounds of trademark law, and now that single-single sense marks, such as color
alone, have been upheld, ﬂavor protection is not unlikely.210That pharmaceutical companies have begun to
pursue trademark protection for ﬂavor marks is the most compelling evidence that the bounds of protection
may soon be extended. In France, Eli Lilly has applied to register the strawberry-like taste of a popular
French candy for the liquid form of Seclor.211 While it has been suggested that the subjectivity in ﬂavor
perception weighs against ﬂavor protection,212similar counter-arguments to those used with respect to color
and scent protection can overcome this assertion; courts could reason that since all sensory perceptions are
subjective, this assertion is not suﬃciently compelling.213
208Hammersley, supra note 178, at 151-153.
209William R. Warner & Co., 265 U.S. at 529.
210See Hammersley, supra note 178, at 121-122 (suggesting that “future [ﬂavor mark] applicants can use successful arguments
for color and scent registration and apply them to advocate ﬂavor marks registrability”).
211Telephone Interview with Robert E. Lee, Jr., Asst. Gen. Pat. Coun., Law Div., Eli Lilly & Co. (Jan. 3, 2003). Although Eli
Lilly intends to abandon this application due to cost-cutting and decreased emphasis on the particular drug involved, protection
may continue to be pursued if taken on as a pro-bono matter.
212See Nancy L. Clarke, Note: Issues in the Federal Registration of Flavors as Trademarks for Pharmaceutical Products, 1993
U. Ill. L. Rev. 105, 127, 131 (1993).
213See supra notes 188–194 and accompanying text.
41Flavor marks must also avoid functionality hurdles in order to be protected. A ﬂavor’s ability to mask a
drug’s natural ﬂavor may not necessarily bar protection. If the original ﬂavor is truly unpalatable, then
a ﬂavor mark will be deemed functional under the utilitarian functionality doctrine,214despite the avail-
ability of alternative ﬂavors.215However, if the original ﬂavor is simply medicinal, albeit unpleasant, the
added ﬂavor’s enhancement of taste could be viewed as a form of aesthetic functionality; the ﬂavor makes
a consumer’s experience more pleasurable than it would be otherwise. Consequently, if there are feasible
ﬂavor alternatives that could also mask the natural ﬂavor,216and if the exclusive right to use the ﬂavor in
question would not signiﬁcantly strain competition, then under the Qualitex rationale, protection would
remain available.217The theory that for ﬂavor mark analyses, aesthetic functionality merges with utilitarian
functionality because palatable ﬂavors can increase patient compliance218is, itself, unpalatable. Patients’
ﬂavor preferences vary, making it unlikely that a doctor would be able to predict which ﬂavor, among several
palatable alternatives,219would most likely increase compliance. Assertions of ﬂavor functionality for creat-
ing a placebo eﬀect220or for serving as a particular suspension medium221may, however, be more diﬃcult to
214See Clarke, supra note 212, at 128. (citing H.C. Ansel, Introduction to Pharmaceutical Dosage Forms 67 (1959)).
215Assessments of utilitarian functionality do not take into account competitive need. See supra notes 35, 59, 180-182 and
accompanying text.
216The availability of alternatives seems likely since thousands of ﬂavors exist. See, e.g., 21 CFR 172.510 (2003) for a list of
over one hundred natural ﬂavoring substances and food additives permitted for direct addition to food for human consumption.
217See supra notes 180-181, 183 and accompanying text.
218See Clarke, supra note 212 at 130.
219In order to qualify for protection, more than one such ﬂavor must be possible. See supra notes 180-181, 183 and accompa-
nying text.
220Id. at 129 (citing A. Leslie, Ethics and Practice of Placebo Therapy, Am. J. Med. 854, 859 (1954) that “people tend to be
skeptical of medications that do not look, taste, or smell like ‘medicine.”’).
221See William R. Warner & Co., 265 U.S. at 531; Clarke, supra note 212, at 129-130.
42defeat.222
E. Liquid Medications
Strong opposition has been voiced against color alone protection in liquid medications despite Qualitex, but
protection for colored liquids may still be attainable. Historically, courts have denied trademark protection
to colored liquids.223Since liquids cannot have patterns or other variations of single colors, the color depletion
argument may be somewhat more compelling in this context:
When a liquid is colored, the conﬁguration of the color is necessarily ‘solid,’ ‘applied all over,’ and
‘without variation.’...With respect to colors of liquids, there truly is a relatively limited number
of arrangements available, and removing one could unduly handicap competitors. Colors of liquids,
therefore, may be the only context in which the ‘color depletion’ argument has some merit and
viability.224
Moreover, if the availability of diﬀerent-colored liquids is truly more limited than that of colored capsules
and tablets, then exclusive use grants would also impede competition, and this protection would be barred
under the Qualitex doctrine of aesthetic functionality.225However, the color alone protection permitted in
Qualitex was not based on the wide variability of a color’s application, but instead on the availability
of color alternatives.226Thus, as long as other ‘solid’ colors can replace the trademarked color of a liquid
222See Clarke, supra note 212, at 128-130.
223See Norwich Pharmacal, 271 F.2d at 572 (denying protection to pink to liquid stomach medicine); Warner Lambert, 718 F.
F. Supp. at 396 (denying protection to amber mouthwash); William R. Warner & Co., 265 U.S. at 531-533 (denying protection
to chocolate-ﬂavored quinine).
225Qualitex, 514 U.S. at 169.
226Id. at 168.
43medication,227this type of protection should not be denied.
V.
Modern Practice of Brand Pharmaceuticals
The availability of trademark protection continues to increase and a few pharmaceutical manufacturers
have begun to take advantage of the newly expanded trademark doctrine. AstraZeneca’s publicity for
its anti-ulcer medication as a “purple pill” epitomizes the type of trademark protection now available to
pharmaceutical manufacturers. Introduced in 1989 to treat heartburn, purple Prilosec228was the best sell-
ing drug in the world in 2000.229Prilosec’s longer-lasting replacement, Nexium, was also distributed in
the same color and similarly promoted as the “purple pill” in both advertisements and on the website
www.purplepill.com.230Consequently, AstraZeneca created a “purple brand” that “is even more important
than the individual products that use it.”231However, AstraZeneca’s emphasis on product design is excep-
tional, rather than representative of industry practice. Overall, even though the current status of trade
dress and trademark law for product design generally bodes well for brand name manufacturers, the prac-
227See supra, note 165 and accompanying text for a discussion of the wide spectrum of colors.
228Note that Prilosec was marketed under the name Losec in some markets outside of the U.S..
229See Pharma Brands Capture Hearts and Minds, supra note 9; see also All Things Considered, National Public Radio (Apr.
18, 2002),
http://www.bamcoalition.org/News/HW/04.18.02.htm.
230On the website, www.purplepill.com, viewers are urged to their doctors “about the Purple Pill called NEXIUM.” The
purple tablet is featured throughout, and as a user drags the mouse over the “About Nexium” page, the mouse’s path is
highlighted by a trail of purple tablets. http://www.purplepill.com/about/20.aboutnexium.asp (last visited Mar. 3, 2003).
Information about Nexium’s predecessor, Prilosec can be found at http://www.priloseconline.com (last visited Mar. 3, 2003).
231Pharma Brands Capture Hearts and Minds, supra note 9.
44tice of trademarking individual design features and pursuing trade dress protection to preclude look-alike
generics appears to be relatively rare. Examination of pharmaceutical companies’ strategies and practices
reveals that issues of timing, funding, chance recognition of the feature, as well as the potential for run-ins
with other brand manufacturers, may inﬂuence manufacturers’ decisions to publicize and protect distinctive
design features of pharmaceuticals.
Proper pursuit of trademark and trade dress protection requires a signiﬁcant amount of planning, and since
the expanded trademark doctrine is relatively new, most pharmaceutical manufacturers may have simply
missed the boat for their current products. A trademark attorney advised that:
To increase the likelihood of securing nontraditional trademarks for pharmaceuticals, the legal team
in charge of intellectual property should coordinate with several other departments within the com-
pany to discuss and plan for a nontraditional trademark protection program. Speciﬁcally, the intel-
lectual property team should develop a registration and enforcement strategy to maximize the value
of the nontraditional mark by coordination with (1) manufacturing to prove non-functionality and
build it into product planning; (2) regulatory to understand what brand signals will be encountered
and used by patients, pharmacists and physicians; and (3) marketing to build nontraditional mark
into advertising campaign and to include appropriate look for advertising.232
This process for securing protection should also be initiated “early in the product life cycle” and “well
in advance of patent expiration.”233Ideally, this strategy should begin during the clinical phase of a drug’s
development: once the naming process is complete, the conception of a drug’s color, ﬂavor, shape and overall
product packaging should begin.234Yet, while strategic planning is clearly advantageous, in some instances,
protection may be achieved without it. AstraZeneca did not ﬁle for registration of the purple color of its
Prilosec tablets until eleven years after the medication was introduced to the market.235Consequently, timing
233Id.
234Telephone Interview with James L. Detorre, President and CEO, and Christopher Nikides, General Counsel, Brand Institute
(Apr. 2, 2003).
235Reg. 76103792 to AstraZeneca ﬁled on Aug. 4, 2000.
45is probably not the most compelling explanation for manufacturers’ hesitancy to protect pharmaceutical
design features.
Money, however, is most likely a determining factor in whether or not trademark protection is sought. Al-
though applications for trademark registration cost only about three hundred dollars, the marketing budget
needed for a product to achieve secondary meaning can be quite substantial.236Moreover, even if pharmaceu-
tical companies can aﬀord to suﬃciently promote a drug’s unique features, they may choose to allocate this
money for other types of marketing, such as informing the public about a drug’s function.237Consequently, it
is possible that product design features are promoted – and thus protected against copying – for only those
drugs whose primary function is already commonly known, such as Tylenol.238This theory may shed light
on why Viagra’s design, the “little blue friend”239was heavily promoted, as well. Along with the common
knowledge explanation, the focus on appearance over function has also been attributed to a rise in popu-
larity of “lifestyle drugs.”240Since drugs such as Prozac, Viagra and Xenical remedy “conditions hitherto
not considered as true ‘diseases,”’ building brand association through appearance may take precedence over
publicizing the function of a, perhaps, non-essential remedy.241The attention given to Valium’s distinctive
shape,V-shaped perforations within a round, ﬂat-faced tablet, might also lend credence to the lifestyle drug
236Telephone Interview with Larry Rickles, Trademark Attorney, Johnson & Johnson Co. (Jan. 3, 2003); see supra notes
20-28 and accompanying text for a discussion of expenditures suﬃcient to show secondary meaning has been acquired; see supra
notes 18-19, 175-179 and accompanying text for a discussion of when secondary meaning is required.
237Telephone Interview with Larry Rickles, supra note 236.
238Id.; see McNeil, 919 F. Supp. at 202, 205 (ﬁnding that the Tylenol manufacturer’s promotion of the red and yellow
gelcaps would likely be suﬃcient to show secondary meaning at trial, and ordering a preliminary injunction against defendant
manufacturer of a look-alike generic).
239Former Senator and presidential candidate Bob Dole appeared in television commercials for Viagra, referring to it as his
“little blue friend.” See Pharma Brands Capture Hearts and Minds, supra note 9.
240Pharma Brands Capture Hearts and Minds, supra note 9.
241Id.
46theory. It is also possible that promotion eﬀorts for drugs such as Viagra focus on design, rather than func-
tion because the related medical condition is a quite sensitive topic.242In addition, pharmaceutical companies
may also focus on design features where a prescription product is expected to be switched to OTC status
in the future, so that consumers will remain loyal to the brand version when choosing medication on their
own. In sum, under any of these scenarios, more funding is available for the promotion of a drug’s design
since less money is allocated for publicity concerning the drug’s function.
Public acceptance of a particular design also factors into the amount of attention brand manufacturers de-
vote to design protection. Certainly, concentrating on a particular design feature of a medication prescribed
only for terminally ill patients in the end stages of their malady would be ineﬀective and thus unlikely. In
contrast, other drugs have received so much publicity, that their design features have become source indica-
tors by accident. When ﬁrst introduced, Prozac’s manufacturer, Eli Lilly & Co., did not intend to register
Prozac’s green and cream color combination.243However, as Prozac became widely-recognized and received
great publicity, the green and cream colors surfaced on the covers of books and magazines referring to Prozac.
According to an in-house trademark attorney, Eli Lilly then realized that this color combination had become
an “alter ego” of the brand name and ﬁled for registration of the combination in 1996.244However, as the
Prozac phenomenon is probably exceptional, rather than a common occurrence, manufacturers should con-
duct consumer research surveys to document the levels of brand recognition associated with speciﬁc design
features.
242Pﬁzer, the manufacturer of Viagra, could not be reached for comment.
243Telephone Interview with Robert E. Lee, Jr., supra note 211.
244Id.
47Perhaps the current strength of the trademark and trade dress doctrine suﬃces to dissuade generic man-
ufacturers from copying pharmaceutical product design, lessening the need for brands to be aggressive in
seeking protection. Losing the battle over a particular color can be costly for a generic manufacturer even
above the costs of legal fees and/or damage awards; if a generic manufacturer receives FDA approval for a
look-alike medication with certain color dyes and is subsequently barred from manufacturing the drug in that
color, then the generic must seek FDA re-approval for the drug’s diﬀerent color additives before being able
to reenter the market.245As a result, the fewer look-alikes produced, the less incentive brand manufacturers
have to register such marks and the fewer cases that arise claiming look-alike trademark and trade dress
infringement. Moreover, even if generic manufacturers do engage in such copying, they may be more willing
to settle out of court because of the present state of the law.
Brand manufacturers seeking protection may also encounter opposition from other leading companies in the
industry, and perhaps this a stronger deterrent than the threat of battling against a generic. Although
the evolution of trademark protection is generally thought of as a struggle between brand and generic
manufacturers, brand name competitors will also contest any assertion of ownership that they fear will
impede their ability to compete in the marketplace. Brand versus brand clashes are also less predictable
because brands that contest certain marks, themselves seek trademark protection for other design features.
For example, Schering-Plough has both aggressively pursued trademark protection for some of its own
designs and actively challenged other companies’ attempts to receive protection.246While Schering-Plough
has ﬁled for trademark protection of its unique color combinations and tablet designs,247it has taken the
245Id.
246Telephone Interview with Joel Wiener, supra note 207.
247Id. (noting Schering-Plough’s trademark registrations for the “yellowish” canister with orange tip color combination of the
Proventil inhaler, and for the rounded, multifaceted tablet design with a star cut-out).
48position that trademarks should not be awarded for single color pharmaceutical products.248Schering-Plough
also has an opposition pending against Smithkline Beecham’s trademark application for the shape of a
capsule with tapered ends for a drug called Diazide.249 While this industry practice of selective approval
for trademark protection could be a basis for criticizing pharmaceutical design protection, this additional
hurdle to protection should probably be viewed as a further safeguard against superﬂuous protection. Each
self-interested actor will, where economically feasible, aggressively pursue trademark protection, regardless
of whether or not such protection is actually warranted. If all of the brand manufacturers joined forces to
stretch trademark protection as far as possible, then there would be a risk – albeit small if the PTO and
courts remain vigilant – that this powerful lobby might succeed in achieving improper protection. However,
if each company seeking such protection must prevail over the protestations of both generic and other brand
name competitors, then there should be no cartel-like inﬂuences on the outcome. Schering-Plough asserts
that single colors for pharmaceutical products are not suﬃciently distinctive, and company policy would
change only if a color were “extremely unique” and heavily promoted.250In fact, these requirements are
no diﬀerent from those established in Qualitex,251and Schering-Plough’s eﬀorts to preclude protection of
single colors that fail to meet these requirements simply helps assure that appropriate trademark protection
boundaries remain in place. Individual brand manufacturers may appear to be drawing arbitrary lines in the
sand, justifying trademark protection for those aspects which they deem important and criticizing awards of
protection for those aspects which would only be beneﬁcial to other members of the industry. Yet this lack
of industry solidarity helps level the playing ﬁeld between the brand name and generic manufacturers and
248Id. (maintaining that single colors of pharmaceuticals are not distinctive and that patients rely on the pharmaceutical
colors to identify the type of drug, rather than the manufacturer).
249Id.
250Id.
251See supra notes 171-173 and accompanying text; see also supra notes 175-179 and accompanying text for a discussion of
whether or not color alone can be inherently distinctive.
49allows only balanced protection to prevail.
VI. Conclusion
A 1993 article in Fortune magazine simply stated that “generic [versions of brand name drugs] can’t come in
capsules of the same size, shape, or color.”252Although this may be an overstatement, it accurately reﬂects
the general sentiment that the law in this area strongly favors original manufacturers.
Trademark and trade dress law has evolved, becoming more sympathetic to the creators of original designs
and more antagonistic towards those attempting to free-ride on a creator’s promotional eﬀorts. To succeed
in claims of unprivileged imitation, brand manufacturers must show secondary meaning, disprove opponents’
claims of functionality, and establish that copying will cause a likelihood of confusion. Brand manufacturers
may also be able to pursue vicarious liability for pharmacists’ passing oﬀ look-alikes. Moreover, in some
instances, brand manufacturers can win a preliminary injunction against look-alike generics if there is suf-
ﬁcient evidence that the trade dress originator would be irreparably harmed, that the balance of equities
weighs in favor of the movant, and that the public would thereby be best served. Finally, the Supreme
Court’s approval of a color alone trademark reinforced this trend and should encourage more pharmaceutical
manufacturers to take advantage of this doctrine where all statutory requirements have been met.
As with any other type of investment, money should be allocated based on expected income. Investments
should be made where there is the most to gain and product design can create promising returns. Building
brand recognition not only builds market share, but may also help shield brand manufacturers against liabil-
ity for problems caused by generic versions of the same drug. In fact, the costs associated with liability are so
252Tully, supra note 2. Emphasis added.
50high, that some generic manufacturers are working to diﬀerentiate themselves from brand products to reduce
the risk of legal problems arising from branded products.253 While trademark protection is not yet being
utilized to its full potential, more research is being conducted on pharmaceutical product design than ever
before.254Although emphasis on pharmaceutical product design may have been conﬁned to lifestyle drugs
or other speciﬁc categories in the past, the increasing competitiveness of the industry as well as the risks
of misplaced liability and infringement suits make product design important for all drugs.255Pharmaceutical
product design will only increase in importance in the future and manufacturers who fail to pursue branding
through distinctive coloring, shaping, and ﬂavoring will be at a signiﬁcant disadvantage.
253Telephone Interview with James L. Detorre and Christopher Nikides, supra note 234.
254Id.
255Id.
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